内科学
危险系数
医学
置信区间
癌症
肿瘤科
前瞻性队列研究
背景(考古学)
循环肿瘤DNA
阶段(地层学)
比例危险模型
生物标志物
胃肠病学
化疗
生物
古生物学
生物化学
作者
Shuqiang Yuan,Run‐Cong Nie,You‐Sheng Huang,Yingbo Chen,Siyu Wang,Xiaowei Sun,Yuanfang Li,Ze‐Kun Liu,Yan‐Xing Chen,Yi-Chen Yao,Yu Kang T. Xu,Haibo Qiu,Yao Liang,Wei Ting Wang,Zexian Liu,Qi Zhao,Rui‐Hua Xu,Zhiwei Zhou,Feng Wang
出处
期刊:癌症:英文版
日期:2023-10-14
卷期号:43 (12): 1312-1325
被引量:41
摘要
BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker for predicting relapse in multiple solid cancers. However, the predictive value of ctDNA for disease recurrence remains indefinite in locoregional gastric cancer (GC). Here, we aimed to evaluate the predictive value of ctDNA in this context. METHODS: From 2016 to 2019, 100 patients with stage II/III resectable GC were recruited in this prospective cohort study (NCT02887612). Primary tumors were collected during surgical resection, and plasma samples were collected perioperatively and within 3 months after adjuvant chemotherapy (ACT). Somatic variants were captured via a targeted sequencing panel of 425 cancer-related genes. The plasma was defined as ctDNA-positive only if one or more variants detected in the plasma were presented in at least 2% of the primary tumors. RESULTS: Compared with ctDNA-negative patients, patients with positive postoperative ctDNA had moderately higher risk of recurrence [hazard ratio (HR) = 2.74, 95% confidence interval (CI) = 1.37-5.48; P = 0.003], while patients with positive post-ACT ctDNA showed remarkably higher risk (HR = 14.99, 95% CI = 3.08-72.96; P < 0.001). Multivariate analyses indicated that both postoperative and post-ACT ctDNA positivity were independent predictors of recurrence-free survival (RFS). Moreover, post-ACT ctDNA achieved better predictive performance (sensitivity, 77.8%; specificity, 90.6%) than both postoperative ctDNA and serial cancer antigen. A comprehensive model incorporating ctDNA for recurrence risk prediction showed a higher C-index (0.78; 95% CI = 0.71-0.84) than the model without ctDNA (0.71; 95% CI = 0.64-0.79; P = 0.009). CONCLUSIONS: Residual ctDNA after ACT effectively predicts high recurrence risk in stage II/III GC, and the combination of tissue-based and circulating tumor features could achieve better risk prediction.
科研通智能强力驱动
Strongly Powered by AbleSci AI